Interesting Image

¹⁸F-FDG PET/MRI Image of Skin Metastasis of Ovarian Cancer

10.4274/mirt.galenos.2022.97268

• Ali Kibar
• Sertaç Asa
• Rabia Lebriz Uslu Beşli
• Muhammet Sait Sağer
• Kerim Sönmezoğlu

Received Date: 24.05.2022 Accepted Date: 24.05.2022 Mol Imaging Radionucl Ther 2023;32(2):159-161 PMID: 37337862

• Abstract
• Full Text
• Video - Image
• References
• 3
• 380

Ovarian cancer is one of the deadliest tumors among women. It mostly metastasizes to the liver, pleura, lungs, and bones. We present a sixty-six-year-old patient with skin lesions. The patient who underwent biopsy due to skin lesions was diagnosed with ovarian cancer. ¹⁸F-fluorodeoxyglucose (FDG) positron emission tomography/magnetic resonance imaging (PET/MRI) performed for metastasis search shows widespread skin involvement, especially in the lower abdomen and legs. Skin involvement it ovarian cancer can be rarely seen, and in this article we would like to share ¹⁸F-FDG PET/MRI of skin involvement in ovarian cancer.

Keywords: 18F-FDG PET, PET/MRI, ovarian cancer, skin metastasis

Ethics

Informed Consent: Obtained.

Peer-review: Externally peer-reviewed.

Authorship Contributions

Surgical and Medical Practices: A.K, S.A, R.L.U.B, M.S.S., K.S., Concept: A.K., S.A., Design: A.K., S.A., R.L.U.B., Data Collection or Processing: A.K., S.A., R.L.U.B., Analysis or Interpretation: A.K., S.A., Literature Search: A.K., Writing: A.K., S.A.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study received no financial support.

Images

1. Otsuka I. Cutaneous metastases in ovarian cancer. Cancers (Basel) 2019;11:1292.
2. Khiewvan B, Torigian DA, Emamzadehfard S, Paydary K, Salavati A, Houshmand S, Werner TJ, Alavi A. An update on the role of PET/CT and PET/MRI in ovarian cancer. Eur J Nucl Med Mol Imaging 2017;44:1079-1091.
3. Sun J, Cui XW, Li YS, Wang SY, Yin Q, Wang XN, Gu L. The value of 18F-FDG PET/CT imaging combined with detection of CA125 and HE4 in the diagnosis of recurrence and metastasis of ovarian cancer. Eur Rev Med Pharmacol Sci 2020;24:7276-7283.
4. Liu S, Feng Z, Wen H, Jiang Z, Pan H, Deng Y, Zhang L, Ju X, Chen X, Wu X. 18F-FDG PET/CT can predict chemosensitivity and proliferation of epithelial ovarian cancer via SUVmax value. Jpn J Radiol 2018;36:544-550.
5. Nie J, Zhang J, Gao J, Guo L, Zhou H, Hu Y, Zhu C, Li Q, Ma X. Diagnostic role of 18F-FDG PET/MRI in patients with gynecological malignancies of the pelvis: a systematic review and meta-analysis. PLoS One 2017;12:e0175401. Erratum in: PLoS One 2018;13:e0202314. 
6. Tempany CM, Zou KH, Silverman SG, Brown DL, Kurtz AB, McNeil BJ. Staging of advanced ovarian cancer: comparison of imaging modalities--report from the Radiological Diagnostic Oncology Group. Radiology 2000;215:761-767.
7. Tsuyoshi H, Tsujikawa T, Yamada S, Okazawa H, Yoshida Y. Diagnostic value of [18F]FDG PET/MRI for staging in patients with ovarian cancer. EJNMMI Res 2020;10:117.
8. Nguyen NC, Beriwal S, Moon CH, D’Ardenne N, Mountz JM, Furlan A, Muthukrishnan A, Rangaswamy B. Diagnostic value of FDG PET/MRI in females with pelvic malignancy-a systematic review of the literature. Front Oncol 2020;10:519440.